Morgan Stanley Reiterates Overweight on Immunocore Hldgs, Maintains $79 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Andrew Galler has reiterated an Overweight rating on Immunocore Hldgs (NASDAQ:IMCR) and maintained a $79 price target.
August 04, 2023 | 9:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Immunocore Hldgs and maintained a $79 price target, indicating a positive outlook for the company.
The Overweight rating from Morgan Stanley indicates that they believe Immunocore Hldgs' stock will outperform the average return of the stocks they cover. The maintained price target of $79 suggests that they believe the stock has potential for growth. This could lead to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100